Single Subconjunctival Injection Formulation Using Sol-gel Mesoporous Silica As a Controlled Release System for Drop-free Post-cataract Surgery Care

Overview

Journal J Cataract Refract Surg

Specialty Ophthalmology

Date 2020 Aug 21

PMID 32818352

Authors

Yaoyao Sun

Kristyn Huffman

William R Freeman

Lingyun Cheng

Affiliations

Soon will be listed here.

Abstract

Purpose: To develop a mesoporous silica drug delivery system and target drop-free care after cataract surgery with a single subconjunctival injection.

Setting: Laboratory.

Design: Experimental animal study.

Methods: Ketorolac was infiltration-loaded into sol-gel mesoporous silica particles encapsulated with poly(allylamine hydrochloride) and poly(sodium 4-styrenesulfonate) using a layer-by-layer adsorption technique (SG-Ket-LBL). The formulation was subjected to an in vitro and in vivo drug release study in addition to ocular toxicology evaluation.

Results: Thermogravimetric analysis revealed that the drug loading efficiency was 4.4% for the SG-Ket-LBL particles. The in vivo safety study demonstrated that the formulation was well tolerated after subconjunctival injection and aqueous humor pharmacokinetics showed sustained therapeutic drug release for the targeted time window of 6 to 8 weeks.

Conclusions: Findings indicated that sol-gel mesoporous silica could be used as a drug carrier for subconjunctival administration. The tested formulation, SG-Ket-LBL, provided therapeutic ketorolac for 6 to 8 weeks, which might be used for a single subconjunctival injection to replace nonsteroidal anti-inflammatory drug eyedrops after cataract surgery.

References

Singh L, Bhattacharyya S, Kumar R, Mishra G, Sharma U, Singh G . Sol-Gel processing of silica nanoparticles and their applications. Adv Colloid Interface Sci. 2014; 214:17-37. DOI: 10.1016/j.cis.2014.10.007. View

Aragona P, Tripodi G, Spinella R, Lagana E, Ferreri G . The effects of the topical administration of non-steroidal anti-inflammatory drugs on corneal epithelium and corneal sensitivity in normal subjects. Eye (Lond). 2000; 14 ( Pt 2):206-10. DOI: 10.1038/eye.2000.55. View

Walters T, Raizman M, Ernest P, Gayton J, Lehmann R . In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. J Cataract Refract Surg. 2007; 33(9):1539-45. DOI: 10.1016/j.jcrs.2007.05.015. View

Dietlein T, Jordan J, Luke C, Schild A, Dinslage S, Krieglstein G . Self-application of single-use eyedrop containers in an elderly population: comparisons with standard eyedrop bottle and with younger patients. Acta Ophthalmol. 2008; 86(8):856-9. DOI: 10.1111/j.1755-3768.2007.01155.x. View

Gira J, Sampson R, Silverstein S, Walters T, Metzinger J, Talamo J . Evaluating the patient experience after implantation of a 0.4 mg sustained release dexamethasone intracanalicular insert (Dextenza™): results of a qualitative survey. Patient Prefer Adherence. 2017; 11:487-494. PMC: 5352246. DOI: 10.2147/PPA.S126283. View

Yilmaz T, Cordero-Coma M, Gallagher M . Ketorolac therapy for the prevention of acute pseudophakic cystoid macular edema: a systematic review. Eye (Lond). 2011; 26(2):252-8. PMC: 3272202. DOI: 10.1038/eye.2011.296. View

Wilson D, Schutte S, Abel S . Comparing the Efficacy of Ophthalmic NSAIDs in Common Indications: A Literature Review to Support Cost-effective Prescribing. Ann Pharmacother. 2015; 49(6):727-34. DOI: 10.1177/1060028015574593. View

Trikha S, Perera S, Husain R, Aung T . The role of lens extraction in the current management of primary angle-closure glaucoma. Curr Opin Ophthalmol. 2015; 26(2):128-34. DOI: 10.1097/ICU.0000000000000128. View

Maggini S, Feci E, Cappelletto E, Girardi F, Palanti S, Di Maggio R . (I/O) hybrid alkoxysilane/zirconium-oxocluster copolymers as coatings for wood protection. ACS Appl Mater Interfaces. 2012; 4(9):4871-81. DOI: 10.1021/am301206t. View

10.

Angelopoulou A, Efthimiadou E, Kordas G . A new approach to fabricate bioactive silica binary and ternary hybrid microspheres. Mater Sci Eng C Mater Biol Appl. 2015; 53:76-82. DOI: 10.1016/j.msec.2015.04.014. View

11.

Ober M, Barile G, Tari S, Tosi G, Tossi G, Schiff W . Measurement of the actual dose of triamcinolone acetonide delivered by common techniques of intravitreal injection. Am J Ophthalmol. 2006; 142(4):597-600. DOI: 10.1016/j.ajo.2006.05.041. View

12.

Sun Y, Huffman K, Freeman W, Sailor M, Cheng L . Intravitreal safety profiles of sol-gel mesoporous silica microparticles and the degradation product (Si(OH)). Drug Deliv. 2020; 27(1):703-711. PMC: 7269085. DOI: 10.1080/10717544.2020.1760401. View

13.

Bucci Jr F, Waterbury L . A randomized comparison of to-aqueous penetration of ketorolac 0.45%, bromfenac 0.09% and nepafenac 0.1% in cataract patients undergoing phacoemulsification. Curr Med Res Opin. 2011; 27(12):2235-9. DOI: 10.1185/03007995.2011.626018. View

14.

Donnenfeld E, Solomon K, Matossian C . Safety of IBI-10090 for inflammation associated with cataract surgery: Phase 3 multicenter study. J Cataract Refract Surg. 2018; 44(10):1236-1246. DOI: 10.1016/j.jcrs.2018.07.015. View

15.

Kessel L, Tendal B, Jorgensen K, Erngaard D, Flesner P, Andresen J . Post-cataract prevention of inflammation and macular edema by steroid and nonsteroidal anti-inflammatory eye drops: a systematic review. Ophthalmology. 2014; 121(10):1915-24. DOI: 10.1016/j.ophtha.2014.04.035. View

16.

Tzelikis P, Vieira M, Hida W, Motta A, Nakano C, Nakano E . Comparison of ketorolac 0.4% and nepafenac 0.1% for the prevention of cystoid macular oedema after phacoemulsification: prospective placebo-controlled randomised study. Br J Ophthalmol. 2014; 99(5):654-8. DOI: 10.1136/bjophthalmol-2014-305803. View

17.

Shimazaki J, Saito H, Yang H, Toda I, Fujishima H, Tsubota K . Persistent epithelial defect following penetrating keratoplasty: an adverse effect of diclofenac eyedrops. Cornea. 1995; 14(6):623-7. View

18.

Duong H, Westfield K, Chalkley T . Ketorolac tromethamine LS 0.4% versus nepafenac 0.1% in patients having cataract surgery. Prospective randomized double-masked clinical trial. J Cataract Refract Surg. 2007; 33(11):1925-9. DOI: 10.1016/j.jcrs.2007.07.017. View

19.

Zanetti F, Fulco E, Pedreira Chaves F, Pinto A, Arieta C, Lira R . Effect of preoperative use of topical prednisolone acetate, ketorolac tromethamine, nepafenac and placebo, on the maintenance of intraoperative mydriasis during cataract surgery: a randomized trial. Indian J Ophthalmol. 2012; 60(4):277-81. PMC: 3442462. DOI: 10.4103/0301-4738.98705. View

20.

Flach A . Topical nonsteroidal antiinflammatory drugs in ophthalmology. Int Ophthalmol Clin. 2002; 42(1):1-11. DOI: 10.1097/00004397-200201000-00003. View